PSTV - Plus Therapeutics Receives Orphan Drug Designation to Rhenium (186Re) Obisbemeda

2023-11-03 07:27:34 ET

DENVER, Colo., Nov 3, 2023 ( www.247marketnews.com )- Plus Therapeutics, Inc. (Nasdaq: PSTV) stated, this morning, that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to rhenium (186Re) obisbemeda for the treatment of breast cancer with leptomeningeal metastases (LM).

Plus Therapeutics is trading at $1.41, up $0.04 (+2.92%), on 218.1K premarket shares traded.

Its 52-week range is $0.9694 to $7.4985. It hit a new 52-week low last week and its next resistance points are yesterday’s high of $1.54 and $1.60, and if it can break through those during the regular trading session, on very strong volume, its setup could allow it to run much higher.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) …

The post Plus Therapeutics Receives Orphan Drug Designation to Rhenium (186Re) Obisbemeda appeared first on 24/7 Market News .

For further details see: